Xu X, Zhao L, Hu X, Zhang P, Wessale J, Bache R, Chen Y
Cardiovascular Division, Department of Medicine, University of Minnesota, The Center of Vascular Biology, Minneapolis, Minnesota 55455, USA.
Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):306-13. doi: 10.1080/15257771003738683.
The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour of transverse aortic constriction (TAC). This study investigated whether a 7-day delay of treatment with the XO inhibitors febuxostat or allopurinol would reverse TAC-induced changes after onset of heart failure (HF). Neither treatment significantly affected TAC-induced LV hypertrophy; only febuxostat caused a modest improvement in LV function ( approximately 10% increase in LV ejection fraction). However, the purine analog allopurinol tended to increase mortality compared with vehicle or febuxostat in HF mice.
非嘌呤选择性黄嘌呤氧化酶（XO）抑制剂非布司他在横断主动脉缩窄（TAC）后1小时内开始治疗时，可减轻小鼠左心室（LV）肥厚和功能障碍的发展。本研究调查了XO抑制剂非布司他或别嘌醇治疗延迟7天是否会逆转心力衰竭（HF）发作后TAC诱导的变化。两种治疗均未显著影响TAC诱导的LV肥厚；只有非布司他使LV功能有适度改善（LV射血分数增加约10%）。然而，与HF小鼠中的赋形剂或非布司他相比，嘌呤类似物别嘌醇有增加死亡率的倾向。
